Skip to main content
CHEChemed CorpHold6.2·$533.36
CHE · Why this verdict

Why Chemed (CHE) is rated HOLD

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictHOLD
Overall score6.2/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis

Engine thesis — one sentence

Chemed carries strong cash conversion and a solid balance sheet, but 95% of revenue depends on government reimbursement and the company has missed earnings estimates in 3 of the last 4 quarters — a combination of structural payer concentration and recent execution shortfalls that justifies a cautious stance while momentum and risk/reward remain unfavorable.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

Approximately 95% of revenue derives from Medicare and Medicaid reimbursement — well above the 70% level flagged as a government-payer cliff — meaning any adverse CMS rate change could materially impair revenue with little offset from commercial or private-pay channels.

→Stable
Bear case
Expectation
Non-government payer revenue grows to more than 10% of total, reducing Medicare and Medicaid dependence below 90%.

CounterGovernment payer concentration provides a high degree of revenue predictability and creates barriers to entry in regulated care settings; if CMS rates hold steady or improve, the same concentration that creates downside risk also anchors stable, recurring revenue.

Free cash flow ran at 134% of net income last period and the Piotroski F-Score is 7 out of 9, indicating that the underlying business generates real cash meaningfully in excess of reported earnings.

→Stable
Quality breakdown
Expectation
Free cash flow as a percentage of net income stays above 110% for the next four quarters, sustaining the cash quality signal.

CounterWith three recent earnings misses, if the shortfall trend reflects genuine operational pressure, cash conversion may deteriorate as margins compress in future reporting periods.

The company has missed consensus earnings estimates in 3 of the last 4 quarters, with an average EPS surprise of negative 4.5% over that window, suggesting estimates have persistently been set above what management can actually deliver.

↑Improving
Catalyst breakdown
Expectation
EPS surprise turns positive and exceeds 3% for 2 consecutive quarters, reestablishing delivery credibility.

CounterThe most recent quarter delivered a beat of 6.6%, which could indicate the miss pattern has bottomed and that estimates have been sufficiently reset to enable more consistent execution going forward.

A death-cross pattern has triggered a hard block on new exposure, price sits below the 200-day moving average with falling volume accumulation confirming net selling pressure, and momentum scores at 3.2 — below the 4.5 minimum needed to clear the gate.

→Stable
Engine gate (failed)
Expectation
Price reclaims and holds above the 200-day moving average for at least 15 consecutive trading days, resolving the death-cross condition.

CounterThe analysis notes the move below the 200-day average is recent and shallow, and characterizes the trend as too early to call definitively — the current weakness may not yet represent a confirmed structural breakdown.

Per-dimension breakdown

Value

5.1/10data confidence 100%
ComponentSub-score
P/E4.9
P/S8.5
EV/EBITDA2.1
Fwd P/E6.7
PEG4.6
Analyst target4.0
  • ▸Forward P/E: 19.2x
  • ▸PEG: 1.86

Quality

6.4/10data confidence 100%
ComponentSub-score
ROE9.0
ROA9.0
Gross margin2.6
Op margin5.3
Net margin5.3
Current ratio3.6
FCF quality7.6
Moat6.1
Piotroski F8.9
  • ▸Excellent ROE: 27%
  • ▸Strong Piotroski F-Score: 8/9

Growth

7.3/10data confidence 67%
ComponentSub-score
Rev growth4.7
EPS growth10.0

Momentum

7.1/10data confidence 100%
ComponentSub-score
RSI4.4
MACD10.0
OBV1.0
MA position9.0
Volume10.0
vol acceleration8.5
  • ▸Overbought (RSI 72)
  • ▸Volume distribution (falling OBV)
  • ▸Above 200-day MA
  • ▸Volume surge (2.2x avg) on up move

Sentiment

6.3/10data confidence 100%
ComponentSub-score
LLM sentiment5.8
Analyst rating6.5
Price target6.6
  • ▸Light analyst coverage (5.0) — signal dampened

Insider

5.9/10data confidence 100%
ComponentSub-score
materiality4.5
insider conviction2.0
holder change10.0
notable moves7.0
  • ▸Modest insider selling — $3,806,260 (0.055% of mkt cap)
  • ▸Institutions accumulating

Peer rank

5.7/10data confidence 80%
ComponentSub-score
value rank1.9
quality rank8.2
growth rank5.9
  • ▸Best-in-class margins

Technical

4.0/10data confidence 100%
ComponentSub-score
bollinger0.0
support resistance4.2
52w position9.0
gap3.0
  • ▸Extreme gap up (7.0%) - may pull back

Risk (lower is worse)

6.4/10data confidence 100%
ComponentSub-score
short interest7.3
days to cover6.7
volatility5.9
put call0.0
implied vol7.1
beta9.9
debt equity8.6
news risk6.0
  • ▸Elevated put/call: 3.12
  • ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Catalyst

6.2/10data confidence 100%
ComponentSub-score
erm5.0
earnings history6.7
earnings timing5.0
surprise avg3.9
dividend safety8.5
news activity8.0
  • ▸Strong earnings: 3B/1M
  • ▸Dividend aristocrat: 0.6% yield

How the verdict was assembled

Engine trigger

Maintain position. Not compelling to add more.

Engine technical detail
verdict_path: L4:PATH_F_HOLD|L3:NEWS_MOD_NO_UPSIDE
Passed (6)
  • MOMENTUM:7.1>=5.5
  • INSIDER:OK
  • 8K:CLEAN
  • EARNINGS_PROXIMITY:118d clear
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
  • ASYMMETRY:-0.5=NEGATIVE
  • HEALTHCARE_GOV_PAYER:HARD_BLOCK
Warning (0)

none

Reward-to-Risk
-0.45
Upside
-3.3%
Downside
7.5%
Sizing output
AVOID

Setup— — No clear chart pattern; technical signals are mixed

EdgeNo clear edge — No clear edge identified

SuitabilityModerate — Balanced profile

Investment implication

None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:7.1>=5.5. Top dim: Growth at 7.3; weakest: Technical at 4.0. No conviction either direction.

The strongest dimensions are Growth at 7.3, Momentum at 7.1, and Quality at 6.4; the weakest are Technical at 4.0, Value at 5.1, and Peer rank at 5.7. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of -0.45 and an engine sizing output of AVOID.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Government Payer Concentration Cliff

    Trip ifNon-government payer revenue grows to more than 10% of total revenue, reducing Medicare and Medicaid share below 90%.

  • P2Strong Cash Conversion Quality

    Trip ifFree cash flow as a percentage of net income falls below 90% for 2 consecutive quarters.

  • P3Deteriorating Earnings Track Record

    Trip ifEPS surprise exceeds 3% for 2 consecutive quarters, restoring a consistent delivery record.

  • P4Negative Momentum Hard Gate Blocks

    Trip ifPrice closes above the 200-day moving average for 15 consecutive trading days, resolving the death-cross pattern.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home › Stocks › CHE › Why this verdict
Why TrendMatrix rates CHE the way it does — verdict reasoning